Oncolytic Adenovirus Type 3 Coding for CD40L Facilitates Dendritic Cell Therapy of Prostate Cancer in Humanized Mice and Patient Samples

Sadia Zafar, Saru Basnet, Inga-Maria Launonen, Dafne Carolina Alves Quixabeira, Joao Santos, Otto Hemminki, Minna Malmstedt, Victor Cervera-Carrascon, Pasi Aronen, Riikka Kalliokoski, Riikka Havunen, Antti Rannikko, Tuomas Mirtti, Mika Matikainen, Anna Kanerva, Akseli Hemminki

Research output: Contribution to journalArticleScientificpeer-review

Original languageEnglish
JournalHuman Gene Therapy
Volume32
Issue number3-4
Pages (from-to)192-202
Number of pages11
ISSN1043-0342
DOIs
Publication statusPublished - 1 Feb 2021
MoE publication typeA1 Journal article-refereed

Fields of Science

  • adenovirus 3
  • CD40 ligand
  • dendritic cells (DCs)
  • prostate cancer
  • tumor microenvironment
  • PHASE-I
  • IMMUNE-RESPONSE
  • GENE-TRANSFER
  • DESMOGLEIN 2
  • IMMUNOTHERAPY
  • LIGAND
  • DIFFERENTIATION
  • PROGRESSION
  • VACCINATION
  • MECHANISMS
  • 11832 Microbiology and virology
  • 318 Medical biotechnology
  • 1184 Genetics, developmental biology, physiology

Cite this